HK1106711A1 - Methods and compositions for treatment of cns disorders - Google Patents
Methods and compositions for treatment of cns disordersInfo
- Publication number
- HK1106711A1 HK1106711A1 HK08100318.7A HK08100318A HK1106711A1 HK 1106711 A1 HK1106711 A1 HK 1106711A1 HK 08100318 A HK08100318 A HK 08100318A HK 1106711 A1 HK1106711 A1 HK 1106711A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compositions
- methods
- treatment
- cns disorders
- cns
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Lubricants (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66929005P | 2005-04-06 | 2005-04-06 | |
US11/285,905 US7619007B2 (en) | 2004-11-23 | 2005-11-22 | Method and composition for administering an NMDA receptor antagonist to a subject |
PCT/US2006/013506 WO2006121560A2 (en) | 2005-04-06 | 2006-04-06 | Methods and compositions for treatment of cns disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1106711A1 true HK1106711A1 (en) | 2008-03-20 |
Family
ID=37036831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08100318.7A HK1106711A1 (en) | 2005-04-06 | 2008-01-10 | Methods and compositions for treatment of cns disorders |
Country Status (18)
Country | Link |
---|---|
US (18) | US8058291B2 (pt) |
EP (2) | EP1874282B1 (pt) |
JP (1) | JP5666087B2 (pt) |
KR (1) | KR101406456B1 (pt) |
CN (1) | CN101247795B (pt) |
AT (1) | ATE481096T1 (pt) |
AU (1) | AU2006244297A1 (pt) |
BR (1) | BRPI0607017B8 (pt) |
CA (1) | CA2604052C (pt) |
DE (1) | DE602006016934D1 (pt) |
DK (1) | DK1874282T3 (pt) |
HK (1) | HK1106711A1 (pt) |
IL (1) | IL186504A0 (pt) |
MX (1) | MX2007012374A (pt) |
PL (1) | PL1874282T3 (pt) |
RU (1) | RU2007140348A (pt) |
WO (1) | WO2006121560A2 (pt) |
ZA (1) | ZA200709535B (pt) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
WO2004034963A2 (en) * | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
AU2005209310B2 (en) * | 2004-01-29 | 2011-01-06 | Neuromolecular, Inc. | Combination of a NMDA receptor antagonist and a MAO-inhibitor or a GADPH-inhibitor for the treatment of central nervous system-related conditions |
US20050245460A1 (en) * | 2004-02-13 | 2005-11-03 | Meyerson Laurence R | Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
EP2623099A1 (en) | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Composition and method for treating neurological disease |
US20060159753A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
AU2005320547B2 (en) | 2004-12-27 | 2009-02-05 | Eisai R & D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
DE602006016934D1 (de) | 2005-04-06 | 2010-10-28 | Adamas Pharmaceuticals Inc | Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen |
GB0519274D0 (en) * | 2005-09-21 | 2005-11-02 | Arakis Ltd | The treatment of neurodegenerative diseases |
US20090169617A1 (en) * | 2006-04-26 | 2009-07-02 | Panagiotis Keramidas | Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix |
RU2009103658A (ru) * | 2006-07-05 | 2010-08-10 | Тева Фармасьютикал Индастриес Лтд. (Il) | Фармацевтические композиции мемантина |
GB0624757D0 (en) * | 2006-12-12 | 2007-01-17 | Sosei R & D Ltd | Novel compounds |
WO2009091932A2 (en) * | 2008-01-18 | 2009-07-23 | Adamas Pharmaceuticals, Inc. | Treatment of mild dementia of the alzheimer's disease type |
TWI491395B (zh) | 2009-09-30 | 2015-07-11 | Ct Lab Inc | 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方 |
BR112012013487A2 (pt) | 2009-12-02 | 2017-10-03 | Adamas Pharmaceuticals Inc | Composições de amantadina e métodos de uso |
JP6082250B2 (ja) * | 2010-02-09 | 2017-02-15 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 認知機能を改善するための方法および組成物 |
US20110251239A1 (en) * | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
US9662347B2 (en) * | 2010-05-11 | 2017-05-30 | Gachon University Of Industry-Academic Cooperation Foundation | Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system |
DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
EP2588104B1 (en) | 2010-07-01 | 2014-12-10 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
US20130209549A1 (en) * | 2010-07-21 | 2013-08-15 | University Of South Florida | Materials and methods for treating neurodegenerative diseases |
JP2013539790A (ja) | 2010-10-12 | 2013-10-28 | ザ ジョンズ ホプキンス ユニバーシティ | メマンチンを含む鎮咳組成物 |
DE102010053432A1 (de) * | 2010-12-06 | 2012-06-06 | Euroimmun Medizinische Labordiagnostika Ag | Verfahren zum Nachweis von anti-NMDA-Rezeptor Autoantikörpern zum Einsatz in Diagnoseverfahren |
AU2012214303A1 (en) * | 2011-02-09 | 2013-09-12 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
US20130323309A1 (en) * | 2011-02-17 | 2013-12-05 | Lupin Limited | Sustained Release Composition of Memantine |
EP2752188B1 (en) * | 2011-08-31 | 2020-05-06 | Toyo Ink Sc Holdings Co., Ltd. | Adhesive patch |
SG11201406690SA (en) * | 2012-04-18 | 2014-11-27 | Contera Pharma Aps | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
ES2813558T3 (es) | 2012-06-19 | 2021-03-24 | Univ Florida | Composiciones y métodos para el tratamiento de enfermedades |
UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
WO2014111790A2 (en) * | 2013-01-15 | 2014-07-24 | Zydus Technologies Limited | Stable transdermal pharmaceutical drug delivery system comprising rivastigmine |
BR112015020771A2 (pt) * | 2013-02-28 | 2017-07-18 | Lupin Ltd | composição farmacêutica de liberação temporizada |
KR102241112B1 (ko) * | 2013-02-28 | 2021-04-15 | 루핀 리미티드 | 특정한 체외 용해 프로파일 또는 약리역학 파라미터를 갖는 도네페질의 약제학적 조성물 |
CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
CN105377371A (zh) * | 2013-04-12 | 2016-03-02 | 西奈山伊坎医学院 | 创伤后应激障碍的治疗方法 |
WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
US20160220512A1 (en) * | 2013-09-15 | 2016-08-04 | Rubicon Research Private Limited | Modified release pharmaceutical formulations |
US20160317465A1 (en) * | 2013-12-12 | 2016-11-03 | Hisamitsu Pharmaceutical Co., Inc. | Cover material-equipped patch and cover material-equipped patch kit |
CA3214846A1 (en) * | 2014-02-04 | 2015-08-13 | Forest Laboratories Holdings Limited | Donepezil compositions and methods of treating alzheimer's disease |
TWI602585B (zh) | 2014-03-25 | 2017-10-21 | 林信湧 | 一種用於治療阿茲海默症之吸入式醫藥組成物及其備製方法 |
ES2822562T3 (es) * | 2014-10-03 | 2021-05-04 | Lachesis Biosciences Ltd | Composiciones intranasales para el tratamiento de enfermedades y trastornos neurológicos y degenerativos |
US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
EP3909569A1 (en) | 2014-11-04 | 2021-11-17 | Adamas Pharmaceuticals, Inc. | Methods of administering amantadine compositions |
ITUB20150635A1 (it) * | 2015-04-14 | 2016-10-14 | Giuseppe Lotito | Uso di un inibitore dell’aceticolinesterasi e composizioni farmaceutiche contenenti detto inibitore. |
KR20180022661A (ko) * | 2015-05-07 | 2018-03-06 | 엑소반트 사이언시즈 게엠베하 | 신경퇴행성 질환을 치료하는 방법 |
NZ738682A (en) | 2015-05-22 | 2022-01-28 | Agenebio Inc | Extended release pharmaceutical compositions of levetiracetam |
WO2017029299A1 (en) * | 2015-08-17 | 2017-02-23 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Antibody or antibody fragment or non-ig scaffold binding to a binding region of an anti-n-methyl-d-aspartate (nmda) receptor antibody |
KR101882224B1 (ko) * | 2015-09-02 | 2018-07-26 | 한국프라임제약주식회사 | 콜린 알포세레이트 및 메만틴을 함유하는 복합 조성물 |
CN105326837A (zh) * | 2015-10-09 | 2016-02-17 | 北京万全德众医药生物技术有限公司 | 一种盐酸美金刚缓释-多奈哌齐速释复方胶囊 |
AU2016381366A1 (en) | 2015-12-30 | 2018-06-28 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
EP3474831A1 (en) | 2016-06-23 | 2019-05-01 | Corium International, Inc. | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
CN109789113A (zh) | 2016-07-27 | 2019-05-21 | 考里安国际公司 | 美金刚透皮递送系统 |
EP3490559A1 (en) | 2016-07-27 | 2019-06-05 | Corium International, Inc. | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
US20180028463A1 (en) | 2016-07-27 | 2018-02-01 | Corium International Inc. | Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug |
WO2018062941A1 (ko) * | 2016-09-30 | 2018-04-05 | 주식회사 바이오파마티스 | 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
CN110325214A (zh) * | 2016-12-22 | 2019-10-11 | Rvx疗法有限公司 | 用于预防和治疗神经元损伤的低剂量药物组合 |
JP7317002B2 (ja) * | 2017-05-19 | 2023-07-28 | ビスケイン ニューロセラピューティクス,インコーポレイテッド | フペルジンの放出調節医薬組成物およびその使用方法 |
AU2018320946B2 (en) | 2017-08-24 | 2024-05-02 | Adamas Pharma, Llc | Amantadine compositions, preparations thereof, and methods of use |
JP7481794B2 (ja) | 2017-10-18 | 2024-05-13 | 日東電工株式会社 | ロール体 |
WO2019104020A1 (en) * | 2017-11-22 | 2019-05-31 | Panorama Research, Inc. | Aminoadamantyl nitrate compounds and their use to treat cns disorders |
US11173132B2 (en) | 2017-12-20 | 2021-11-16 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
KR102224918B1 (ko) * | 2018-03-20 | 2021-03-09 | (주)인벤티지랩 | 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법 |
WO2020208398A1 (es) | 2019-04-09 | 2020-10-15 | Laboratorios Bagó S.A. | Composición farmacéutica en polvo con memantina y donepecilo para utilizar en el tratamiento de la enfermedad de alzheimer |
US11602507B2 (en) | 2019-05-27 | 2023-03-14 | Trikona Pharmaceuticals Pvt. Ltd | Extended release oral composition of memantine or its salt and its process for the preparation |
EP3843702B1 (en) | 2019-05-31 | 2023-07-05 | Tecnimede, Sociedade Técnico-Medicinal, SA | Immediate release fixed-dose combination of memantine and donepezil |
KR20220047970A (ko) * | 2019-06-28 | 2022-04-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 알츠하이머병의 치료를 위한 비강내 단트롤렌 투여 |
WO2021234475A1 (en) * | 2020-05-21 | 2021-11-25 | Pellets Pharma Limited | Modified release compositions and methods of memantine hcl extended release, donepezil hcl immediate release pellets |
CU20200087A7 (es) | 2020-11-24 | 2022-07-08 | Centro De Neurociencias De Cuba | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer |
WO2023077122A1 (en) * | 2021-11-01 | 2023-05-04 | Nitrase Therapeutics, Inc. | Methods of diagnosing a synucleinopathy |
WO2024099974A1 (en) * | 2022-11-07 | 2024-05-16 | Rejuvenate Biomed Nv | Galantamine minitablets |
Family Cites Families (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3152180A (en) | 1960-08-25 | 1964-10-06 | Studiengesellschaft Kohle Mbh | Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines |
US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
GB1173492A (en) | 1966-02-18 | 1969-12-10 | Upjohn Co | Acylamino-Adamantane Derivatives |
FR2219159A1 (en) | 1973-02-23 | 1974-09-20 | Commissariat Energie Atomique | Adamantane nitroxide radicals - antiviral and anticancer agents, also useful in nuclear resonance magnetometry |
US3992518A (en) | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
US4284444A (en) | 1977-08-01 | 1981-08-18 | Herculite Protective Fabrics Corporation | Activated polymer materials and process for making same |
US4148896A (en) * | 1978-02-22 | 1979-04-10 | E. I. Du Pont De Nemours And Company | Antidepressant combination |
DE2856393C2 (de) * | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP0064646B1 (en) | 1981-04-24 | 1991-02-27 | E.R. Squibb & Sons, Inc. | Use for the manufacture of oral forms of nadolol for treating glaucoma |
US4346112A (en) * | 1981-06-29 | 1982-08-24 | University Patents Inc. | Composition and method for treating patients having Parkinson's Disease |
JPS584718A (ja) | 1981-06-30 | 1983-01-11 | Nippon Chibagaigii Kk | 新規適応症に用うる医薬製剤 |
DK150008C (da) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
ATE59302T1 (de) | 1984-07-24 | 1991-01-15 | Key Pharma | Klebende schicht zur transdermalen freigabe. |
US4769027A (en) * | 1984-08-15 | 1988-09-06 | Burroughs Wellcome Co. | Delivery system |
IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
IT1188212B (it) | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
ATE55245T1 (de) * | 1986-04-16 | 1990-08-15 | Asta Pharma Ag | Synergistische kombination von amantadin und selegilin. |
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US4861800A (en) | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
US4878913A (en) * | 1987-09-04 | 1989-11-07 | Pfizer Hospital Products Group, Inc. | Devices for neural signal transmission |
US4904681A (en) * | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
GB8807504D0 (en) | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
US5061721A (en) * | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
US5334618A (en) * | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
ES2059602T3 (es) | 1989-04-14 | 1994-11-16 | Merz & Co Gmbh & Co | Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral. |
JP3158435B2 (ja) | 1989-10-26 | 2001-04-23 | 日本新薬株式会社 | 徐放性製剤 |
CA2045175C (en) | 1989-11-06 | 2003-03-18 | Arthur I. Skoultchi | Production of proteins using homologous recombination |
IT1237904B (it) | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
CA2037178A1 (en) | 1990-02-28 | 1991-08-29 | Albert Walter Brzeczko | Deprenyl/l-dopa/carbidopa pharmaceutical composition |
NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
US5192550A (en) * | 1990-05-07 | 1993-03-09 | Alza Corporation | Dosage form for treating central nervous system disorders |
US5190763A (en) * | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5221536A (en) * | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5057321A (en) * | 1990-06-13 | 1991-10-15 | Alza Corporation | Dosage form comprising drug and maltodextrin |
US5086072A (en) * | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
IN172468B (pt) * | 1990-07-14 | 1993-08-14 | Asta Medica Ag | |
EP0488959A3 (en) | 1990-11-28 | 1992-08-05 | Sandoz Ltd. | New uses of competitive nmda receptor antagonists |
GB9104854D0 (en) | 1991-03-07 | 1991-04-17 | Reckitt & Colmann Prod Ltd | Sustained release compositions |
US5614560A (en) * | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
US5455279A (en) | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
US6764697B1 (en) | 1991-06-27 | 2004-07-20 | Alza Corporation | System for delaying drug delivery up to seven hours |
US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
KR100221695B1 (ko) | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
DE4225730C2 (de) * | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
DE4236752A1 (de) | 1992-10-30 | 1994-05-05 | Asta Medica Ag | Kombinationspräparat aus Flupirtin und Morphin zur Behandlung von Schmerzen und zur Vermeidung der Morphin-Abhängigkeit |
US5358721A (en) * | 1992-12-04 | 1994-10-25 | Alza Corporation | Antiviral therapy |
CA2115792C (en) | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
US5648087A (en) * | 1993-03-09 | 1997-07-15 | Sanofi Sante Nutrition Animale | Anaesthetic pharmaceutical composition comprising a general anaesthetic and selegiline |
AU676315B2 (en) | 1993-06-30 | 1997-03-06 | Takeda Chemical Industries Ltd. | Stabilized solid pharmaceutical preparation and method of producing the same |
CA2161538A1 (en) * | 1993-07-22 | 1995-02-02 | S. Shirley Yang | Controlled release tacrine drug delivery systems and methods for preparing same |
US6908910B2 (en) | 1993-08-06 | 2005-06-21 | The Children's Medical Center Corporation | Estrogenic compounds as anti-mitotic agents |
RU2160093C2 (ru) | 1993-11-16 | 2000-12-10 | Скайефарма Инк. | Везикулы с регулируемым высвобождением активных ингредиентов |
US5395626A (en) | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
US5484608A (en) * | 1994-03-28 | 1996-01-16 | Pharmavene, Inc. | Sustained-release drug delivery system |
US5660848A (en) | 1994-11-02 | 1997-08-26 | The Population Council, Center For Biomedical Research | Subdermally implantable device |
US20020006438A1 (en) | 1998-09-25 | 2002-01-17 | Benjamin Oshlack | Sustained release hydromorphone formulations exhibiting bimodal characteristics |
DE19510189A1 (de) | 1995-03-21 | 1996-09-26 | Hartmut Dr Goebel | Verwendung von Amantadin |
US5677349A (en) * | 1995-04-27 | 1997-10-14 | Gilad; Gad M. | Agmatine for the treatment of neurotrauma and neurodegenerative diseases |
ATE258067T1 (de) | 1995-05-26 | 2004-02-15 | Pfizer | Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält |
DE19528388A1 (de) * | 1995-08-02 | 1997-02-06 | Hans Peter Prof Dr Med Zenner | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs |
AUPN605795A0 (en) * | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
US6095148A (en) * | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
US6395292B2 (en) | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
CA2264182A1 (en) | 1996-08-23 | 1998-02-26 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
US5958919A (en) | 1996-09-20 | 1999-09-28 | Washington University | Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration |
US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
US5919826A (en) | 1996-10-24 | 1999-07-06 | Algos Pharmaceutical Corporation | Method of alleviating pain |
WO1998018452A1 (en) * | 1996-10-25 | 1998-05-07 | Shire Laboratories, Inc. | Soluble form osmotic dose delivery system |
DE19644998C1 (de) * | 1996-10-30 | 1998-06-10 | Hanns Prof Dr Ludwig | Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier |
US6919373B1 (en) | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
JPH10203966A (ja) | 1996-11-21 | 1998-08-04 | Takeda Chem Ind Ltd | 徐放性マイクロカプセルおよびその製造法 |
DE69738966D1 (de) | 1996-12-20 | 2008-10-16 | Mcneil Ppc Inc | Durch ionenaustauscherharze verabreichte hustenmittel |
US6392104B1 (en) * | 1997-03-11 | 2002-05-21 | Daicel Chemical Industries, Ltd. | Adamantane derivatives and process for producing them |
DK0870757T3 (da) * | 1997-04-10 | 2002-07-15 | Pfizer | Fluorsubstituerede adamantanderivater |
AU7472898A (en) | 1997-05-07 | 1998-11-27 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
MA26553A1 (fr) * | 1997-10-17 | 2004-12-20 | Centaur Pharmaceuticals Inc | Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la |
US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
US6007841A (en) * | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
DE19834764A1 (de) * | 1998-08-01 | 2000-02-03 | Univ Hannover | Mittel zur Stabilisierung von Lebensmitteln und kosmetischen Mitteln sowie Verfahren zu dessen Herstellung |
ME00850B (me) | 1998-08-27 | 2008-08-07 | Pfizer Health Ab | Nove perle sa kontrolisanim oslobađanjem, postupak za njihovu proizvodnju i višestruka jedinična formulacija koja ih sadrži |
CA2354472C (en) | 1998-12-17 | 2009-02-24 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
US6797283B1 (en) | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US8545880B2 (en) | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
ATE514445T1 (de) | 1999-03-03 | 2011-07-15 | Optinose As | Nasales verabreichungsgerät |
SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
US6183770B1 (en) | 1999-04-15 | 2001-02-06 | Acutek International | Carrier patch for the delivery of agents to the skin |
US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
WO2001019901A2 (en) | 1999-09-14 | 2001-03-22 | Smithkline Beecham Corporation | Process for making aqueous coated beadlets |
ATE526950T1 (de) | 1999-10-29 | 2011-10-15 | Euro Celtique Sa | Hydrocodon-formulierungen mit gesteuerter freisetzung |
AU1585601A (en) * | 1999-11-04 | 2001-05-14 | Xel Herbaceuticals | Transdermal administration of huperzine |
DE60019334T2 (de) * | 1999-12-09 | 2005-09-08 | Alza Corp., Mountain View | Antivirale arznei |
ATE317868T1 (de) | 1999-12-22 | 2006-03-15 | Nektar Therapeutics Al Corp | Sterisch gehinderte derivate von wasserlöslichen polymeren |
US6491949B2 (en) * | 2000-01-14 | 2002-12-10 | Osmotica Corp. | Osmotic device within an osmotic device |
US6444702B1 (en) | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
US6455066B1 (en) | 2000-03-10 | 2002-09-24 | Epicept Corporation | Intradermal-penetration agents for topical local anesthetic administration |
EP1559418A1 (en) | 2000-06-26 | 2005-08-03 | EpiCept Corporation | Compositions for treating pain of the mucous membrane |
US6648083B2 (en) | 2000-11-02 | 2003-11-18 | Schlumberger Technology Corporation | Method and apparatus for measuring mud and formation properties downhole |
US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
WO2002078615A2 (en) * | 2001-04-02 | 2002-10-10 | Panorama Research, Inc. | Antioxidant nitroxides and nitrones as therapeutic agents |
DE10129265A1 (de) | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
US6500454B1 (en) | 2001-10-04 | 2002-12-31 | Eurand Pharmaceuticals Ltd. | Timed, sustained release systems for propranolol |
EP1485078B1 (en) * | 2002-03-15 | 2012-09-26 | Cypress Bioscience, Inc. | Milnacipran for the treatment of irritable bowel syndrome |
IL149055A0 (en) | 2002-04-09 | 2002-11-10 | Karma Pharm Ltd | Extended release composition comprising as active compound venlafaxine hydrochloride |
TW531966B (en) * | 2002-05-20 | 2003-05-11 | Mediatek Inc | Phase lock loop with low static state phase error and calibration circuit |
US20040102525A1 (en) * | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
AU2003227516B2 (en) * | 2002-05-31 | 2008-03-20 | H. Lundbeck A/S | A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
US6662845B1 (en) | 2002-06-19 | 2003-12-16 | Newell Operating Company | Roman shade with separated backing sheet |
US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
CA2490544C (en) | 2002-06-26 | 2011-04-19 | Alza Corporation | Minimally compliant, volume efficient piston for osmotic drug delivery systems |
BRPI0313148B8 (pt) * | 2002-07-29 | 2021-05-25 | Glaxo Group Ltd | formulações sólidas matriciais de lamotrigina contendo revestimento externo e perfuração em tal revestimento |
US20050208132A1 (en) * | 2002-07-29 | 2005-09-22 | Gayatri Sathyan | Methods and dosage forms for reducing side effects of benzisozazole derivatives |
US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
US6913768B2 (en) | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
US20050075679A1 (en) * | 2002-09-30 | 2005-04-07 | Gliner Bradford E. | Methods and apparatuses for treating neurological disorders by electrically stimulating cells implanted in the nervous system |
TW200418446A (en) * | 2002-10-24 | 2004-10-01 | Merz Pharma Gmbh & Co Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
CN1726012A (zh) * | 2002-12-11 | 2006-01-25 | 辉瑞产品公司 | 活性物质在高脂肪环境中的控制释放 |
EP1572164A2 (en) * | 2002-12-18 | 2005-09-14 | Pain Therapeutics, Inc. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
AU2003302147A1 (en) * | 2002-12-23 | 2004-07-14 | Osmotica Costa Rica Sociedad Anonima | Delivery device containing venlafaxine and memantine and use method thereof |
US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
ES2214129B1 (es) * | 2003-02-13 | 2005-12-01 | Almirall Prodesfarma, S.A. | 3-fenilfuran-2-onas. |
AR043467A1 (es) | 2003-03-05 | 2005-07-27 | Osmotica Argentina S A | Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson |
US20050065219A1 (en) * | 2003-03-27 | 2005-03-24 | Lipton Stuart A. | Treatment of demyelinating conditions |
JP2006525989A (ja) * | 2003-05-09 | 2006-11-16 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | Cns障害を治療するためのcrf1受容体アンタゴニストとしてのピラジノン |
EP1638931A4 (en) * | 2003-06-11 | 2007-11-07 | Neuromolecular Inc | METHOD FOR TARGETING A THERAPEUTIC AGENT |
EP1631273A1 (en) | 2003-06-16 | 2006-03-08 | Allergan, Inc. | Memantine oral dosage forms |
US20060079578A1 (en) * | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
KR100524018B1 (ko) * | 2003-07-25 | 2005-10-26 | 삼성전자주식회사 | 이동형 디스플레이장치 및 이동형 디스플레이 시스템 |
US20050037364A1 (en) * | 2003-08-13 | 2005-02-17 | International Business Machines Corporation | Techniques for recording signals |
EP1682109B1 (en) | 2003-10-22 | 2008-10-15 | Merz Pharma GmbH & Co. KGaA | The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic as peptides in amyloidopathies |
WO2005051426A1 (en) * | 2003-11-21 | 2005-06-09 | Memory Pharmaceutical Corporation | Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors |
US20050119249A1 (en) * | 2003-12-02 | 2005-06-02 | Erik Buntinx | Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US7553858B2 (en) | 2003-12-17 | 2009-06-30 | Meda Pharma Gmbh & Co. Kg | Combination of flupirtine and tramadol |
US20050191349A1 (en) * | 2003-12-31 | 2005-09-01 | Garth Boehm | Galantamine formulations |
CA2552221A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
ATE486592T1 (de) | 2004-01-05 | 2010-11-15 | Merz Pharma Gmbh & Co Kgaa | Memantin für die behandlung von leichtem bis mittelschwerem morbus alzheimer |
AU2005209310B2 (en) | 2004-01-29 | 2011-01-06 | Neuromolecular, Inc. | Combination of a NMDA receptor antagonist and a MAO-inhibitor or a GADPH-inhibitor for the treatment of central nervous system-related conditions |
JP2007522249A (ja) * | 2004-02-13 | 2007-08-09 | ニューロモレキュラー・インコーポレイテッド | 精神医学的状態の処置のための、nmdaレセプターアンタゴニストと、抗うつ薬であるmaoインヒビターまたはgadphインヒビターとの併用 |
US20050245460A1 (en) * | 2004-02-13 | 2005-11-03 | Meyerson Laurence R | Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders |
ES2337700T3 (es) | 2004-02-18 | 2010-04-28 | Sepracor, Inc. | Terapia combinada de agonista de dopamina con sedantes para mejorar la calidad del sueño. |
TW200531680A (en) | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
WO2005092009A2 (en) | 2004-03-19 | 2005-10-06 | Axonyx, Inc. | Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders |
CA2569015A1 (en) | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
US20060002999A1 (en) | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
US7346382B2 (en) * | 2004-07-07 | 2008-03-18 | The Cleveland Clinic Foundation | Brain stimulation models, systems, devices, and methods |
US20060052370A1 (en) * | 2004-08-24 | 2006-03-09 | Meyerson Laurence R | Methods and compositions for treating nociceptive pain |
US20060240043A1 (en) * | 2004-10-08 | 2006-10-26 | Meyerson Laurence R | Methods and compositions for treating migraine pain |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
EP2623099A1 (en) * | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Composition and method for treating neurological disease |
US8252331B2 (en) * | 2004-12-03 | 2012-08-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Osmotic device containing amantadine and an osmotic salt |
AR053986A1 (es) | 2004-12-03 | 2007-05-30 | Osmotica Pharmaceutical Argent | Dispositivo osmotico que contiene amantadina y una sal osmotica |
US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
WO2006089066A1 (en) * | 2005-02-15 | 2006-08-24 | Neuromolecular Pharmaceuticals, Inc. | Combinations therapy for treatment of demyelinating conditions |
DE602006016934D1 (de) | 2005-04-06 | 2010-10-28 | Adamas Pharmaceuticals Inc | Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen |
CA2607600A1 (en) * | 2005-06-16 | 2006-12-28 | Forest Laboratories, Inc. | Modified and immediate release memantine bead formulation |
KR101122469B1 (ko) | 2007-04-02 | 2012-07-12 | 파킨슨즈 인스티튜트 | 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물 |
-
2006
- 2006-04-06 DE DE602006016934T patent/DE602006016934D1/de active Active
- 2006-04-06 JP JP2008505658A patent/JP5666087B2/ja active Active
- 2006-04-06 DK DK06749777.6T patent/DK1874282T3/da active
- 2006-04-06 EP EP06749777A patent/EP1874282B1/en not_active Revoked
- 2006-04-06 BR BRPI0607017A patent/BRPI0607017B8/pt active IP Right Grant
- 2006-04-06 CA CA2604052A patent/CA2604052C/en active Active
- 2006-04-06 AT AT06749777T patent/ATE481096T1/de not_active IP Right Cessation
- 2006-04-06 EP EP10075323.5A patent/EP2243475B1/en active Active
- 2006-04-06 KR KR1020077025686A patent/KR101406456B1/ko active IP Right Grant
- 2006-04-06 PL PL06749777T patent/PL1874282T3/pl unknown
- 2006-04-06 RU RU2007140348/15A patent/RU2007140348A/ru not_active Application Discontinuation
- 2006-04-06 MX MX2007012374A patent/MX2007012374A/es active IP Right Grant
- 2006-04-06 US US11/399,879 patent/US8058291B2/en active Active
- 2006-04-06 WO PCT/US2006/013506 patent/WO2006121560A2/en active Application Filing
- 2006-04-06 CN CN2006800166301A patent/CN101247795B/zh active Active
- 2006-04-06 AU AU2006244297A patent/AU2006244297A1/en not_active Abandoned
-
2007
- 2007-10-08 IL IL186504A patent/IL186504A0/en unknown
- 2007-11-06 ZA ZA200709535A patent/ZA200709535B/xx unknown
-
2008
- 2008-01-10 HK HK08100318.7A patent/HK1106711A1/xx not_active IP Right Cessation
-
2010
- 2010-04-02 US US12/753,769 patent/US8293794B2/en active Active
- 2010-04-09 US US12/757,795 patent/US8283379B2/en active Active
-
2012
- 2012-06-28 US US13/536,588 patent/US8338485B2/en active Active
- 2012-06-28 US US13/536,763 patent/US8338486B2/en active Active
- 2012-07-26 US US13/559,478 patent/US20120288560A1/en not_active Abandoned
- 2012-12-21 US US13/725,246 patent/US8580858B2/en active Active
-
2013
- 2013-04-15 US US13/863,140 patent/US20140134243A1/en not_active Abandoned
-
2015
- 2015-02-03 US US14/613,220 patent/US20150297537A1/en not_active Abandoned
-
2016
- 2016-04-04 US US15/090,396 patent/US20160243035A1/en not_active Abandoned
- 2016-04-04 US US15/090,400 patent/US20160250149A1/en not_active Abandoned
- 2016-04-04 US US15/090,416 patent/US20160220545A1/en not_active Abandoned
- 2016-04-04 US US15/090,429 patent/US20160243093A1/en not_active Abandoned
- 2016-04-29 US US15/142,492 patent/US20160250161A1/en not_active Abandoned
- 2016-04-29 US US15/142,133 patent/US20160243094A1/en not_active Abandoned
- 2016-04-29 US US15/142,253 patent/US20160243095A1/en not_active Abandoned
- 2016-04-29 US US15/142,519 patent/US20160243058A1/en not_active Abandoned
-
2017
- 2017-10-23 US US15/790,710 patent/US20180263914A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1106711A1 (en) | Methods and compositions for treatment of cns disorders | |
WO2007016155A3 (en) | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | |
TW200735868A (en) | Compositions and methods for treating CNS disorders | |
WO2007079214A3 (en) | Prokineticin 2 receptor antagonists | |
UA83899C2 (uk) | Сполуки імідазолу для лікування нейродегенеративних розладів | |
EA200600048A1 (ru) | Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором | |
MXPA05012680A (es) | Indoles novedosos de 3-azufre sustituidos. | |
MA31451B1 (fr) | Antagonistes des recepteurs de l'orexine de pyridyl piperidine. | |
DE60045427D1 (de) | Bupropinmetaboliten zur Behandlung von Dementia und anderen zerebrovasckulären Erkrankungen | |
TW200635903A (en) | Therapeutic agents | |
TW200734311A (en) | New compounds | |
TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
WO2007067511A3 (en) | Morpholine carboxamide prokineticin receptor antagonists | |
NO20063275L (no) | Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom | |
TW200633986A (en) | Therapeutic agents | |
EA200971050A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
TW200602297A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
EA200600071A1 (ru) | Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором | |
ATE401072T1 (de) | 1-arylsulfonyl-3-substituierte indol und indolinederivate verwendbar zur behandlung von erkrankungen des zentralnervensystem | |
TW200734324A (en) | Therapeutic agents | |
GB0519760D0 (en) | Novel compounds | |
WO2008057575A3 (en) | Novel arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use | |
ATE402150T1 (de) | Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen | |
RS20080139A (en) | Imidazole coumpounds for the treatment of neurological disorders | |
IL174726A0 (en) | Transgenic animals with serious disorders related to alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170406 |